Imatinib, a tyrosine kinase inhibitor of BCR-ABL, KIT, and platelet-derived growth factor receptor, is used in patients with chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST). Primary and acquired resistance to the drug can occur in both diseases. Molecular mechanisms have been reported in CML and GIST for primary resistance, whereas extensive studies on the mechanisms responsible for secondary resistance have been almost exclusively reported for CML.
A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient / E. Tamborini, L. Bonadiman, A. Greco, V. Albertini, T. Negri, A. Gronchi, R. Bertulli, M. Colecchia, P.G. Casali, M.A. Pierotti, S. Pilotti. - In: GASTROENTEROLOGY. - ISSN 0016-5085. - 127:1(2004 Jul), pp. 294-299.
A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient
T. Negri;P.G. Casali;
2004
Abstract
Imatinib, a tyrosine kinase inhibitor of BCR-ABL, KIT, and platelet-derived growth factor receptor, is used in patients with chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST). Primary and acquired resistance to the drug can occur in both diseases. Molecular mechanisms have been reported in CML and GIST for primary resistance, whereas extensive studies on the mechanisms responsible for secondary resistance have been almost exclusively reported for CML.
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S0016508504002203-main.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
240.51 kB
Formato
Adobe PDF
|
240.51 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
